Corvus Pharmaceuticals (CRVS) Cash from Financing Activities (2015 - 2026)

Corvus Pharmaceuticals' Cash from Financing Activities history runs 11 years deep, the most recent figure standing at $190.7 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 68267.74% year-over-year to $190.7 million in Q1 2026; TTM through Mar 2026 was $226.9 million, a 1098.16% increase from a year earlier, with the FY2025 full-year figure at $36.4 million, down 25.7% from the prior year.
• Cash from Financing Activities advanced to $190.7 million in Q1 2026 per CRVS's latest filing, from $20000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $190.7 million in Q1 2026 and bottomed at $4000.0 in Q1 2023.
• The 4-year median for Cash from Financing Activities is $347500.0 (2023), against an average of $25.4 million.
• Across the five-year window, Cash from Financing Activities plunged 99.89% in 2025 and jumped 68267.74% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $335000.0 in 2023, then jumped by 5454.63% to $18.6 million in 2024, then plunged by 99.89% to $20000.0 in 2025, then surged by 953630.0% to $190.7 million in 2026.
• Per Business Quant, the three latest CRVS Cash from Financing Activities figures stand at $190.7 million (Q1 2026), $20000.0 (Q4 2025), and $360000.0 (Q3 2025).